Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects

NCT01016483 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT01016483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01016483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects
Lead sponsor
EMD Serono
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2009
Completion date
April 30, 2015
Enrollment
141 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma